Conference item icon

Conference item

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Abstract:

OBJECTIVE: The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy. RESEARCH DESIGN AND METHODS: In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.2337/dc08-1355

Authors


Expand authors...
Volume:
32
Issue:
1
Pages:
84-90
Host title:
Diabetes care
Publication date:
2009-01-01
Event location:
United States
DOI:
EISSN:
1935-5548
ISSN:
0149-5992
Source identifiers:
72934

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP